These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 20515470)

  • 21. HUWE1 upregulation has tumor suppressive effect in human prostate cancer cell lines through c-Myc.
    Qu H; Liu H; Jin Y; Cui Z; Han G
    Biomed Pharmacother; 2018 Oct; 106():309-315. PubMed ID: 29966975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PIM1 phosphorylation of the androgen receptor and 14-3-3 ζ regulates gene transcription in prostate cancer.
    Ruff SE; Vasilyev N; Nudler E; Logan SK; Garabedian MJ
    Commun Biol; 2021 Oct; 4(1):1221. PubMed ID: 34697370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor.
    Qu F; Cui X; Hong Y; Wang J; Li Y; Chen L; Liu Y; Gao Y; Xu D; Wang Q
    Mol Cell Biochem; 2013 May; 377(1-2):121-30. PubMed ID: 23417242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation.
    Noura M; Tomita S; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
    Cancer Med; 2024 Jul; 13(13):e7445. PubMed ID: 38940430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
    Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
    Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
    Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
    Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
    Carver BS; Chapinski C; Wongvipat J; Hieronymus H; Chen Y; Chandarlapaty S; Arora VK; Le C; Koutcher J; Scher H; Scardino PT; Rosen N; Sawyers CL
    Cancer Cell; 2011 May; 19(5):575-86. PubMed ID: 21575859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.
    Barfeld SJ; Urbanucci A; Itkonen HM; Fazli L; Hicks JL; Thiede B; Rennie PS; Yegnasubramanian S; DeMarzo AM; Mills IG
    EBioMedicine; 2017 Apr; 18():83-93. PubMed ID: 28412251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and ERG regulation of PIM kinases in prostate cancer.
    Eerola SK; Kohvakka A; Tammela TLJ; Koskinen PJ; Latonen L; Visakorpi T
    Cancer Med; 2021 May; 10(10):3427-3436. PubMed ID: 33932111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why target PIM1 for cancer diagnosis and treatment?
    Magnuson NS; Wang Z; Ding G; Reeves R
    Future Oncol; 2010 Sep; 6(9):1461-78. PubMed ID: 20919829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.
    Hahm ER; Singh KB; Singh SV
    Cell Cycle; 2016 Sep; 15(17):2309-20. PubMed ID: 27341160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
    Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
    Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.
    Aravalli RN; Talbot NC; Steer CJ
    World J Gastroenterol; 2015 Feb; 21(7):2011-29. PubMed ID: 25717234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer.
    Yan B; Yau EX; Samanta S; Ong CW; Yong KJ; Ng LK; Bhattacharya B; Lim KH; Soong R; Yeoh KG; Deng N; Tan P; Lam Y; Salto-Tellez M;
    Gastric Cancer; 2012 Apr; 15(2):188-97. PubMed ID: 21993851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.
    Itkonen HM; Minner S; Guldvik IJ; Sandmann MJ; Tsourlakis MC; Berge V; Svindland A; Schlomm T; Mills IG
    Cancer Res; 2013 Aug; 73(16):5277-87. PubMed ID: 23720054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
    Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
    Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.